Literature DB >> 29386185

TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3.

Youzhou Sang1, Yanxin Li2, Lina Song1, Angel A Alvarez3, Weiwei Zhang1, Deguan Lv1, Jianming Tang1, Feng Liu4, Zhijie Chang5, Shigetsugu Hatakeyama6, Bo Hu3, Shi-Yuan Cheng3, Haizhong Feng7.   

Abstract

Aberrant EGFR signaling is a common driver of glioblastoma (GBM) pathogenesis; however, the downstream effectors that sustain this oncogenic pathway remain unclarified. Here we demonstrate that tripartite motif-containing protein 59 (TRIM59) acts as a new downstream effector of EGFR signaling by regulating STAT3 activation in GBM. EGFR signaling led to TRIM59 upregulation through SOX9 and enhanced the interaction between TRIM59 and nuclear STAT3, which prevents STAT3 dephosphorylation by the nuclear form of T-cell protein tyrosine phosphatase (TC45), thereby maintaining transcriptional activation and promoting tumorigenesis. Silencing TRIM59 suppresses cell proliferation, migration, and orthotopic xenograft brain tumor formation of GBM cells and glioma stem cells. Evaluation of GBM patient samples revealed an association between EGFR activation, TRIM59 expression, STAT3 phosphorylation, and poor prognoses. Our study identifies TRIM59 as a new regulator of oncogenic EGFR/STAT3 signaling and as a potential therapeutic target for GBM patients with EGFR activation.Significance: These findings identify a novel component of the EGFR/STAT3 signaling axis in the regulation of glioma tumorigenesis. Cancer Res; 78(7); 1792-804. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29386185      PMCID: PMC5882560          DOI: 10.1158/0008-5472.CAN-17-2774

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.

Authors:  Yajun Han; Hesham M Amin; Bevin Franko; Christine Frantz; Xinzhe Shi; Raymond Lai
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

2.  JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.

Authors:  Qifan Zheng; Lei Han; Yucui Dong; Jing Tian; Wei Huang; Zhaoyu Liu; Xiuzhi Jia; Tao Jiang; Jianning Zhang; Xia Li; Chunsheng Kang; Huan Ren
Journal:  Neuro Oncol       Date:  2014-05-25       Impact factor: 12.300

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.

Authors:  Hui-Wen Lo; Xinyu Cao; Hu Zhu; Francis Ali-Osman
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

5.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

Review 6.  STAT-mediated EGFR signaling in cancer.

Authors:  Kelly M Quesnelle; Amanda L Boehm; Jennifer R Grandis
Journal:  J Cell Biochem       Date:  2007-10-01       Impact factor: 4.429

7.  STAP-2/BKS, an adaptor/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif.

Authors:  Mayu Minoguchi; Shigeru Minoguchi; Daisuke Aki; Akiko Joo; Tetsuya Yamamoto; Taro Yumioka; Tadashi Matsuda; Akihiko Yoshimura
Journal:  J Biol Chem       Date:  2003-01-22       Impact factor: 5.157

8.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Authors:  Qi-Wen Fan; Christine K Cheng; W Clay Gustafson; Elizabeth Charron; Petra Zipper; Robyn A Wong; Justin Chen; Jasmine Lau; Christiane Knobbe-Thomsen; Michael Weller; Natalia Jura; Guido Reifenberger; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

9.  IGFBP2 potentiates nuclear EGFR-STAT3 signaling.

Authors:  C Y Chua; Y Liu; K J Granberg; L Hu; H Haapasalo; M J Annala; D E Cogdell; M Verploegen; L M Moore; G N Fuller; M Nykter; W K Cavenee; W Zhang
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

10.  TRIM59 Promotes the Proliferation and Migration of Non-Small Cell Lung Cancer Cells by Upregulating Cell Cycle Related Proteins.

Authors:  Weihua Zhan; Tianyu Han; Chenfu Zhang; Caifeng Xie; Mingxi Gan; Keyu Deng; Mingui Fu; Jian-Bin Wang
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

View more
  15 in total

1.  EGFR/EGFRvIII partly regulates the tumourigenesis of glioblastoma through the SOX9-GLUT3 axis.

Authors:  Shenbo Chen; Liangwang Yang; Zhengzheng Li; Shenghua Zhuo; Bo Yan; Zhaoteng Zhang; Jinben Zhang; Haizhong Feng; Kun Yang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Identification of a tripartite motif family gene signature for predicting the prognosis of patients with glioma.

Authors:  Sheng Xiao; Junhua Yu; Xuegang Yuan; Qianxue Chen
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

3.  Nuclear receptor coactivator SRC-1 promotes colorectal cancer progression through enhancing GLI2-mediated Hedgehog signaling.

Authors:  Peng Guo; Qiang Chen; Kesong Peng; Jianyuan Xie; Junjia Liu; Wenjing Ren; Zhangwei Tong; Ming Li; Jianming Xu; Yongyou Zhang; Chundong Yu; Pingli Mo
Journal:  Oncogene       Date:  2022-04-13       Impact factor: 9.867

4.  TRIM59 expression is regulated by Sp1 and Nrf1 in LPS-activated macrophages through JNK signaling pathway.

Authors:  Yanying An; Yuqi Ni; Zhihao Xu; Shuizhen Shi; Jiashu He; Yu Liu; Ke-Yu Deng; Mingui Fu; Meixiu Jiang; Hong-Bo Xin
Journal:  Cell Signal       Date:  2019-12-25       Impact factor: 4.315

Review 5.  The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.

Authors:  Semer Maksoud
Journal:  Mol Neurobiol       Date:  2021-03-04       Impact factor: 5.682

6.  Ubiquitin-specific protease 4 promotes glioblastoma multiforme via activating ERK pathway.

Authors:  Yudong Zhou; Ping Liang; Wenyuan Ji; Zengpeng Yu; Hui Chen; Li Jiang
Journal:  Onco Targets Ther       Date:  2019-03-05       Impact factor: 4.147

7.  An TRIM59-CDK6 axis regulates growth and metastasis of lung cancer.

Authors:  Biao Geng; Manman Liang; Lilong Qin; Wenying Zhao; Hanli Wang; Lijing Wang; Xianhui Pan; Xingwu Chen
Journal:  J Cell Mol Med       Date:  2018-12-04       Impact factor: 5.310

8.  TRIM59 loss in M2 macrophages promotes melanoma migration and invasion by upregulating MMP-9 and Madcam1.

Authors:  Yuan Tian; Yantong Guo; Pei Zhu; Dongxu Zhang; Shanshan Liu; Mengyan Tang; Yuanxin Wang; Zheng Jin; Dong Li; Dongmei Yan; Guiying Li; Xun Zhu
Journal:  Aging (Albany NY)       Date:  2019-10-10       Impact factor: 5.682

9.  Prognostic significance of TRIM59 for cancer patient survival: A systematic review and meta-analysis.

Authors:  Min Wang; Ce Chao; Guanghua Luo; Bin Wang; Xianghong Zhan; Dongmei Di; Yongxiang Qian; Xiaoying Zhang
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 10.  STAT3 signaling in ovarian cancer: a potential therapeutic target.

Authors:  Renba Liang; Xishan Chen; Li Chen; Fangzhu Wan; Kaihua Chen; Yongchu Sun; Xiaodong Zhu
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.